Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2468-2471

  Flamm, Robert K ^a   Sader, Helio S ^a,b   Farrell, David J ^a,c   Jones, Ronald N ^a,d  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF TORONTO   (Canada)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAROLINE; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ERYTHROMYCIN; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; PENICILLINS; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84896977451     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02557-13     Document Type: Article

References (19)

1. Biek D, Critchley IA, Riccobene TA, Thye DA. 2010. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Grampositive activity. J. Antimicrob. Chemother. 65(Suppl 4):iv9 -iv16. http://dx.doi.org/10.1093/jac/ dkq51.
2. Laudano JB. 2011. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J. Antimicrob. Chemother. 66(Suppl 3):iii11-iii18. http://dx.doi.org/10.1093/jac/dkr095.
3. Farrell DJ, Castanheira M, Mendes RE, Sader HS, Jones RN. 2012. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008 -2010). Clin. Infect. Dis. 55(Suppl 3):S206-S214. http://dx.doi.org/10.1093/cid/cis563.
4. Jones RN, Farrell DJ, Mendes RE, Sader HS. 2011. Comparative ceftaroline activity tested against pathogens associated with communityacquired pneumonia: results from an international surveillance study. J. Antimicrob. Chemother. 66(Suppl 3):iii69 -iii80. http://dx.doi.org/10.1093/jac/dkr101.
5. Jones RN, Sader HS, Moet GJ, Farrell DJ. 2010. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn. Microbiol. Infect. Dis. 68:334-336. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.024.
6. Flamm RK, Sader HS, Farrell DJ, Jones RN. 2012. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob. Agents Chemother. 56:2933-2940. http://dx.doi.org/10.1128/AAC.00330- 12.
7. Pfaller MA, Farrell DJ, Sader HS, Jones RN. 2012. AWARE ceftaroline surveillance program (2008 -2010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin. Infect. Dis. 55(Suppl 3):S187-S193. http://dx.doi.org/10.1093/cid/cis561.
8. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030. http://dx.doi.org/10.1128/ AAC.01516-09.
9. Vidaillac C, Leonard SN, Rybak MJ. 2010. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int. J. Antimicrob. Agents 35:527-530. http://dx.doi.org/10.1016/j.ijantimicag.2010.02. 006.
10. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, Sader HS, Jones RN. 2010. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob. Agents Chemother. 54:2716-2719. http://dx.doi.org/10.1128/AAC.01797-09.
11. McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, Beall B, Whitney CG, Klugman KP. 2009. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 53:552-556. http://dx.doi.org/10.1128/ AAC.01324-08.
12. Farrell DJ, Flamm RK, Jones RN, Sader HS. 2013. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). Diagn. Microbiol. Infect. Dis. 75: 86-88. http://dx.doi.org/10.1016/j.diagmicrobio.2012.06.005.
13. Karlowsky JA, Adam HJ, Decorby MR, Lagace-Wiens PR, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients attending Canadian hospitals in 2009. Antimicrob. Agents Chemother. 55:2837-2846. http://dx.doi.org/10.1128/AAC.01787- 10.
14. Moisan H, Pruneau M, Malouin F. 2010. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J. Antimicrob. Chemother. 65:713-716. http://dx.doi.org/10.1093/jac/ dkp503.
15. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1676. http://dx.doi.org/10.1128/AAC.00019-10.
16. Sader HS, Flamm RK, Farrell DJ, Jones RN. 2012. Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. Clin. Infect. Dis. 55(Suppl 3): S181- S186. http://dx.doi.org/10.1093/cid/cis560.
17. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
18. Clinical and Laboratory Standards Institute. 2013. M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Forest Laboratories, Inc. 2013. Teflaro® package insert. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/200327s009lbl.pdf. Accessed January 2014.